Estimated Long-Term Benefits of Finerenone in Heart Failure: A Prespecified Secondary Analysis of the FINEARTS-HF Randomized Clinical Trial.

Vaduganathan M, Claggett BL, Desai AS, Jhund PS, Lam CSP, Senni M, Shah SJ, Voors AA, Zannad F, Pitt B, Borentian M, Lay-Flurrie J, Viswanathan P, Behmenburg FU, McMurray JJV, Solomon SD

Finerenone in Patients With a Recent Worsening Heart Failure Event: The FINEARTS-HF Trial.

Desai AS, Vaduganathan M, Claggett BL, Kulac IJ, Jhund PS, Cunningham J, Borentain M, Lay-Flurrie J, Viswanathan P, Rohwedder K, Amarante F, Lam CSP, Senni M, Shah SJ, Voors AA, Zannad F, Pitt B, Kosiborod M, McMurray JJV, Solomon SD

Finerenone, Obesity, and Heart Failure With Mildly Reduced/Preserved Ejection Fraction: Prespecified Analysis of FINEARTS-HF.

Butt JH, Henderson AD, Jhund PS, Claggett BL, Desai AS, Lay-Flurrie J, Viswanathan P, Lage A, Scheerer MF, Lam CSP, Senni M, Shah SJ, Voors AA, Bauersachs J, Fonseca C, Kosiborod MN, Linssen GCM, Petrie MC, Schou M, Verma S, Zannad F, Pitt B, Vaduganathan M, Solomon SD, McMurray JJV

Initial Decline in Glomerular Filtration Rate With Finerenone in HFmrEF/HFpEF: A Prespecified Analysis of FINEARTS-HF.

Matsumoto S, Jhund PS, Henderson AD, Bauersachs J, Claggett BL, Desai AS, Brinker M, Schloemer P, Viswanathan P, Mares JW, Scalise A, Lam CSP, Linssen GCM, Kerr Saraiva JF, Senni M, Troughton R, Udell JA, Voors AA, Zannad F, Pitt B, Vaduganathan M, Solomon SD, McMurray JJV

Effect of Finerenone on the KCCQ in Patients With HFmrEF/HFpEF: A Prespecified Analysis of FINEARTS-HF.

Yang M, Henderson AD, Talebi A, Atherton JJ, Chiang CE, Chopra V, Comin-Colet J, Kosiborod MN, Kerr Saraiva JF, Claggett BL, Desai AS, Kolkhof P, Viswanathan P, Lage A, Lam CSP, Senni M, Shah SJ, Rohwedder K, Voors AA, Zannad F, Pitt B, Vaduganathan M, Jhund PS, Solomon SD, McMurray JJV

Effects of the Nonsteroidal MRA Finerenone With and Without Concomitant SGLT2 Inhibitor Use in Heart Failure.

Vaduganathan M, Claggett BL, Kulac IJ, Miao ZM, Desai AS, Jhund PS, Henderson AD, Brinker M, Lay-Flurrie J, Viswanathan P, Scheerer MF, Lage A, Lam CSP, Senni M, Shah SJ, Voors AA, Zannad F, Pitt B, McMurray JJV, Solomon SD

Efficacy and Safety of Finerenone Across the Ejection Fraction Spectrum in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Prespecified Analysis of the FINEARTS-HF Trial.

Docherty KF, Henderson AD, Jhund PS, Claggett BL, Desai AS, Mueller K, Viswanathan P, Scalise A, Lam CSP, Senni M, Shah SJ, Voors AA, Zannad F, Pitt B, Vaduganathan M, Solomon SD, McMurray JJV

Finerenone in Women and Men With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Secondary Analysis of the FINEARTS-HF Randomized Clinical Trial.

Chimura M, Wang X, Jhund PS, Henderson AD, Claggett BL, Desai AS, Fonseca C, Goncalvesova E, Katova T, Mueller K, Glasauer A, Rohwedder K, Viswanathan P, Nodari S, Lam CSP, Saldarriaga CI, Senni M, Sharma K, Voors AA, Zannad F, Pitt B, Vardeny O, Vaduganathan M, Solomon SD, McMurray JJV

Finerenone, Serum Potassium, and Clinical Outcomes in Heart Failure With Mildly Reduced or Preserved Ejection Fraction.

Vardeny O, Vaduganathan M, Claggett BL, Desai AS, Jhund PS, Lam CSP, Senni M, Shah SJ, Voors AA, Zannad F, Pitt B, Matsumoto S, Merkely B, Zieroth S, Yilmaz MB, Lay-Flurrie J, Viswanathan P, Horvat-Broecker A, Scalise A, McMurray JJV, Solomon SD

The role of zinc in the premature brain: functions, outcomes and future research perspectives.

Chamakioti M, Brion LP, Viswanathan P, Lair CS, Angelis D

Finerenone in heart failure and chronic kidney disease with type 2 diabetes: FINE-HEART pooled analysis of cardiovascular, kidney and mortality outcomes.

Vaduganathan M, Filippatos G, Claggett BL, Desai AS, Jhund PS, Henderson A, Brinker M, Kolkhof P, Schloemer P, Lay-Flurrie J, Viswanathan P, Lam CSP, Senni M, Shah SJ, Voors AA, Zannad F, Rossing P, Ruilope LM, Anker SD, Pitt B, Agarwal R, McMurray JJV, Solomon SD

Author Correction: Finerenone in heart failure and chronic kidney disease with type 2 diabetes: FINE-HEART pooled analysis of cardiovascular, kidney and mortality outcomes.

Vaduganathan M, Filippatos G, Claggett BL, Desai AS, Jhund PS, Henderson A, Brinker M, Kolkhof P, Schloemer P, Lay-Flurrie J, Viswanathan P, Lam CSP, Senni M, Shah SJ, Voors AA, Zannad F, Rossing P, Ruilope LM, Anker SD, Pitt B, Agarwal R, McMurray JJV, Solomon SD

Comparative Long-Term Outcomes of Formocresol, Mineral Trioxide Aggregate, and Laser Pulpotomy Techniques in Primary Teeth.

Suprakasam S, Kakkachi Parambil RS, Hari K, Viswanathan P, Abraham I, Mathai ET

Association of gut microbiota with allograft injury in kidney transplant recipients: a comparative profiling through 16S metagenomics and quantitative PCR.

Charles P, Kumar S, Girish Kumar CP, Parameswaran S, Viswanathan P, Nachiappa Ganesh R

Gamified Behavioral Science Intervention to Enhance Trial Enrollment: An Embedded Study Within the FINEARTS-HF Trial.

Bhatt AS, Chatur S, Claggett BL, Lay-Flurrie J, Viswanathan P, Vardeny O, Kosiborod MN, Sharma K, Solomon SD, Vaduganathan M